209 related articles for article (PubMed ID: 32726929)
1. BMI1-Mediated Pemetrexed Resistance in Non-Small Cell Lung Cancer Cells Is Associated with Increased SP1 Activation and Cancer Stemness.
Shen HT; Chien PJ; Chen SH; Sheu GT; Jan MS; Wang BY; Chang WW
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32726929
[TBL] [Abstract][Full Text] [Related]
2. miR-145-5p Targets Sp1 in Non-Small Cell Lung Cancer Cells and Links to BMI1 Induced Pemetrexed Resistance and Epithelial-Mesenchymal Transition.
Chang WW; Wang BY; Chen SH; Chien PJ; Sheu GT; Lin CH
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499676
[TBL] [Abstract][Full Text] [Related]
3. The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids.
Chiu LY; Hsin IL; Yang TY; Sung WW; Chi JY; Chang JT; Ko JL; Sheu GT
Oncogene; 2017 Jan; 36(2):242-253. PubMed ID: 27270426
[TBL] [Abstract][Full Text] [Related]
4. High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase.
Kuo WT; Tu DG; Chiu LY; Sheu GT; Wu MF
Oncol Rep; 2017 Nov; 38(5):2787-2795. PubMed ID: 28901493
[TBL] [Abstract][Full Text] [Related]
5. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
6. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
[TBL] [Abstract][Full Text] [Related]
7. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
Liao KS; Wei CL; Chen JC; Zheng HY; Chen WC; Wu CH; Wang TJ; Peng YS; Chang PY; Lin YW
Regul Toxicol Pharmacol; 2016 Nov; 81():353-361. PubMed ID: 27693704
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment.
Gao Y; Dorn P; Liu S; Deng H; Hall SRR; Peng RW; Schmid RA; Marti TM
Cancer Cell Int; 2019; 19():317. PubMed ID: 31798346
[TBL] [Abstract][Full Text] [Related]
9. Dexamethasone pretreatment impairs the thymidylate synthase inhibition mediated flare in thymidine salvage pathway activity in non-small cell lung cancer.
Chen X; Yang Y; Katz SI
PLoS One; 2018; 13(8):e0202384. PubMed ID: 30142195
[TBL] [Abstract][Full Text] [Related]
10. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV
Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517
[TBL] [Abstract][Full Text] [Related]
11. BMI1, ALDH1A1, and CD133 Transcripts Connect Epithelial-Mesenchymal Transition to Cancer Stem Cells in Lung Carcinoma.
Koren A; Rijavec M; Kern I; Sodja E; Korosec P; Cufer T
Stem Cells Int; 2016; 2016():9714315. PubMed ID: 26770215
[TBL] [Abstract][Full Text] [Related]
12. A dynamic Boolean network reveals that the BMI1 and MALAT1 axis is associated with drug resistance by limiting miR-145-5p in non-small cell lung cancer.
Gupta S; Silveira DA; Piedade GPS; Ostrowski MP; Mombach JCM; Hashimoto RF
Noncoding RNA Res; 2024 Mar; 9(1):185-193. PubMed ID: 38125755
[TBL] [Abstract][Full Text] [Related]
13. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
14. Antiaging gene Klotho regulates epithelial-mesenchymal transition and increases sensitivity to pemetrexed by inducing lipocalin-2 expression.
Takegahara K; Usuda J; Inoue T; Sonokawa T; Matsui T; Matsumoto M
Oncol Lett; 2021 May; 21(5):418. PubMed ID: 33841579
[TBL] [Abstract][Full Text] [Related]
15. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
17. Targeting cancer stemness mediated by BMI1 and MCL1 for non-small cell lung cancer treatment.
Lin EH; Hsu JW; Lee TF; Hsu CF; Lin TH; Jan YH; Chang HY; Cheng CM; Hsu HJ; Chen WW; Chen BH; Tsai HF; Li JJ; Huang CY; Chuang SH; Chang JM; Hsiao M; Wu CW
J Cell Mol Med; 2022 Aug; 26(15):4305-4321. PubMed ID: 35794816
[TBL] [Abstract][Full Text] [Related]
18. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells.
Jiang P; Xu C; Chen L; Chen A; Wu X; Zhou M; Haq IU; Mariyam Z; Feng Q
Mol Carcinog; 2018 Dec; 57(12):1835-1844. PubMed ID: 30182373
[TBL] [Abstract][Full Text] [Related]
19. LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.
Wang B; Chen Q; Cao Y; Ma X; Yin C; Jia Y; Zang A; Fan W
PLoS One; 2016; 11(12):e0168904. PubMed ID: 28033430
[TBL] [Abstract][Full Text] [Related]
20. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.
Chamizo C; Zazo S; Dómine M; Cristóbal I; García-Foncillas J; Rojo F; Madoz-Gúrpide J
BMC Pulm Med; 2015 Oct; 15():132. PubMed ID: 26502926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
